Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation

NCT06732180 is registered in ClinicalTrials.gov with Gain Therapeutics, Inc. as lead sponsor.

NCT NCT06732180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation
Lead sponsor
Gain Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 21, 2025
Completion date
November 30, 2025
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease